Fractyl Health (NASDAQ:GUTS) Rating Lowered to Sell at Wall Street Zen

Fractyl Health (NASDAQ:GUTS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

GUTS has been the topic of a number of other reports. Craig Hallum started coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They set a “buy” rating and a $4.00 target price on the stock. Weiss Ratings lowered Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, June 4th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.12.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $0.68 on Friday. The stock has a market cap of $108.24 million, a PE ratio of -0.77 and a beta of 2.32. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $2.44. The company’s 50-day moving average price is $0.76 and its 200-day moving average price is $0.66. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Equities research analysts forecast that Fractyl Health will post -0.53 earnings per share for the current year.

Insider Transactions at Fractyl Health

In other Fractyl Health news, Director William Bradley bought 68,493 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the acquisition, the director directly owned 84,622 shares in the company, valued at approximately $61,774.06. The trade was a 424.66% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ian Sheffield bought 35,000 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the acquisition, the director owned 35,000 shares in the company, valued at $25,550. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders purchased 171,493 shares of company stock valued at $127,150. 8.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of GUTS. Jane Street Group LLC bought a new position in shares of Fractyl Health during the second quarter valued at approximately $31,000. Jump Financial LLC bought a new position in Fractyl Health in the fourth quarter worth approximately $57,000. Scientech Research LLC bought a new position in Fractyl Health in the third quarter worth approximately $49,000. Sanctuary Advisors LLC purchased a new stake in Fractyl Health during the second quarter worth $26,000. Finally, Prelude Capital Management LLC purchased a new stake in Fractyl Health during the third quarter worth $55,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.